Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T cell impact rituximab-mediated NK cell transcriptomics

ABSTRACT: T cell impact rituximab-mediated NK cell transcriptomics

PROVIDER: PRJNA688891 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13336665_1.fastq.gz	Fastqsanger.gz
	SRR13336665_2.fastq.gz	Fastqsanger.gz
	SRR13336666_1.fastq.gz	Fastqsanger.gz
	SRR13336666_2.fastq.gz	Fastqsanger.gz
	SRR13336667_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

T cell impact rituximab-mediated NK cell transcriptomics

Project description:We found that T cells impacted rituximab-mediated NK cell viability, ability to mediate antibody dependent cellular cytotoxicity, and phenotypical changes in vitro. To understand the effects of T cells on ritxuimab-mediated NK cell responses at the transcriptional lvel, we performed bulk mRNA sequencing of NK cells in different experimental settings.

2021-07-13 | GSE164086 | GEO

SUMOylation inhibitor TAK-981 potentiates rituximab activity by Type I IFN-dependent macrophage and NK cell stimulation

Project description:SUMOylation is a reversible post-translational modification that has been implicated in the regulation of various cellular processes including inflammatory responses and expression of Type I interferons (IFN1). In this report, we have explored the activity of the selective small molecule SUMOylation inhibitor TAK-981 in promoting antitumor innate immune responses. We demonstrate that treatment with TAK-981 results in IFN1-dependent macrophage and NK cell activation, promoting macrophage phagocytosis and NK cell cytotoxicity in ex vivo assays. Furthermore, pre-treatment with TAK-981 enhanced macrophage phagocytosis or NK cell cytotoxicity against CD20-positive target cells in combination with the anti-CD20 antibody rituximab. In vivo studies demonstrated synergistic antitumor activity of TAK-981 and rituximab in CD20-positive lymphoma xenograft models. TAK-981 is currently being studied in phase 1 clinical trials (NCT03648372, NCT04074330, NCT04776018, and NCT04381650) for the treatment of patients with lymphomas and solid tumors.

2024-04-24 | GSE185841 | GEO

Obesity and adverse SDoH impact NK cell function

Project description:Obesity and adverse SDoH impact NK cell function

| PRJNA1166336 | ENA

Anesthesia, TIVA, Balanced Anesthesia, NK Cell

Project description:Anesthetic method was reported to have an impact on postoperative long-term outcome in cancer patients. In this study, we will investigate the effect of different anesthetic methods on NK cell activity, cytokine response and postoperative outcome in colorectal cancer patients undergoing CRS and HIPEC. We will compare propofol-based total intravenous anesthesia (TIVA) with balanced anesthesia to determine the effect of propofol, inhalation agent, and opioid on tumor genesis, recurrence, NK cell activity, cytokine response, and postoperative outcome.

| 66979 | ecrin-mdr-crc

NK cell

Project description:NK cell Transcriptome

| PRJNA1097286 | ENA

SUMOylation inhibitor TAK-981 potentiates rituximab activity by Type I IFN-dependent macrophage and NK cell stimulation

Project description:SUMOylation inhibitor TAK-981 potentiates rituximab activity by Type I IFN-dependent macrophage and NK cell stimulation

| PRJNA770982 | ENA

Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapse

Project description:Single-cell transcriptomics was performed to investigate the bone marrow NK cell compartment of myeloma patients at diagnosis (n=19), during treatment (n=21) and at relapse (n=6). The bone marrow of myeloma patients is characterized by a reduction in conventional cytotoxic NK cells that persists throughout treatment. We show in 20% of newly diagnosed myeloma patients that an altered balance between cytotoxic and cytokine-producing NK cells translates into a reduced cytotoxic ability in response to therapeutic antibodies. The relative loss of cytotoxic NK cells persists at relapse and is accompanied by an expansion of IFN-responsive NK cells. These findings reveal previously unappreciated alterations in bone marrow NK cell composition and highlight the importance of understanding the bone marrow immune system in patients receiving immunotherapies.

2023-07-18 | E-MTAB-13157 | biostudies-arrayexpress

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Project description:This phase II trial studies giving rituximab before and after a donor peripheral blood stem cell transplant in patients with B-cell lymphoma that does not respond to treatment (refractory) or has come back after a period of improvement (relapsed). Monoclonal antibodies, such as rituximab, can interfere with the ability of cancer cells to grow and spread. Giving rituximab before and after a donor peripheral blood stem cell transplant may help stop cancer from coming back and may help keep the patient’s immune system from rejecting the donor’s stem cells.

| 2069746 | ecrin-mdr-crc

Obesity and adverse SDoH impact NK cell function

Project description:African American (AA) women are disproportionally affected by obesity, particularly in the setting of adverse social determinants of health (aSDoH), which contribute to cardiovascular disease (CVD) and cancer disparities. Obesity and aSDoH appear to impair Natural Killer cells (NKs), which are critical in the innate immune response; however, the underlying mechanisms are largely unknown. We sought to investigate signaling pathways involved in NK dysfunction related to obesity in AA women from under-resourced neighborhoods disproportionately exposed to aSDoH. We determined in freshly isolated NK cells that obesity and higher social isolation, as well as higher depression and lower socioeconomic status, are associated with a shift in NK cell subsets away from CD56dim/CD16+ cytotoxic NK cells. Using ex vivo data, we identified LDL as a serum marker related to NK cell function in an AA population from under-resourced neighborhoods. Additionally, NK cells from AA women with obesity and LDL-treated NK cells displayed a loss in NK cell function. Comparative unbiased RNA sequencing analysis revealed DUSP1-dependent signaling as a common factor. Subsequent experiments involving chemical inhibition of DUSP1 signaling and DUSP1 overexpression in NK cells highlighted the significance of DUSP1 in lysosome biogenesis and, ultimately, NK cell function. Our data demonstrate a pathway by which obesity in the setting of aSDoH may relate to NK dysfunction, making DUSP1 an important target for further investigation of CVD and cancer disparities.

2025-02-12 | GSE278321 | GEO

Expression data from the rituximab-resistant lymphoma cell lines and the parental cell lines

Project description:Rituximab, a monoclonal antibody against CD20, has achieved great success in the treatment of B cell lymphoma, but many patients have shown resistance to it and led to disease progression eventually. At present, the mechanism of resistance is still not clear, but we consider that it may involve the multiple genes and multiple signaling pathways. Therefore, our study aimed at searching differentially expressed genes of rituximab resistant cell lines (RRCL) by cDNA microarray, and exploring the resistant mechanism of RRCL by using the subsequent bioinformatics methods. In this study, we successfully identified seventy up-regulated genes and forty-two down-regulated genes in both two RRCL. We also isolated the MAPK signaling pathway, which was the significantly enriched pathway in resistant mechanism, through KEGG pathway analysis. Moreover, we discovered the biological behaviors of RRCL that mainly inhibit apoptosis, promote cellular proliferation, transcription and angiogenesis through Gene Ontology (GO) terms analysis. In conclusion, our results suggested that the most closely related pathway to rituximab resistance was MAPK signaling pathway, which may partly be related to its inhibiting the apoptosis of cells and promoting the proliferation of cells and vascular development. We utilized human mantle cell lymphoma cell line Jeko-1 and human Burkitt lymphoma cell line Raji to establish rituximab resistant Jeko-1/R and Raji/R cell lines. And then, in order to explore rituximab resistant mechanism, we looked for the different gene expression profile of rituximab resistant cell lines compared with the parental cell lines by cDNA microarray and carried out subsequent KEGG pathway and GO terms analysis.

2014-08-13 | E-GEOD-60327 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data